Recruiting
Phase 3

Corneal Collagen Cross-linking

Sponsor:

Rush Eye Associates

Code:

NCT01708538

Conditions

Corneal Ectasia Disorders Including Keratoconus

Eligibility Criteria

Sex: All

Age: 10 - 70

Healthy Volunteers: Not accepted

Interventions

CXL

Study Details

Brief summary:

The corneal collagen cross-linking treatment has been used with increasing success to treat corneal dystrophies such as "keratoconus." Recent advances have allowed different techniques for performing this cross-linking treatment. This study investigates the effects of corneal cross-linking using different surgical techniques.

Conditions

Corneal Ectasia Disorders Including Keratoconus

Study ID

NCT01708538

Start date

Oct, 2012

Status verified date

Oct, 2022

Completion date

Oct, 2024

Anticipated

Primary completion date

Oct, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 10 - 70

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age 10-70, willing to participate, diagnosis of corneal ectasia disorder

Exclusion Criteria:

  • Unwilling or unable to participate in trial

Study Design

Enrollment

30 participants

Anticipated

Allocation

Randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Epithelium on

Epi not removed during CXL treatment

active comparator: Epithelium off

Epi removed before CXL treatment

Interventions

CXL

corneal crosslinking

Primary outcome measure

  • Visual acuity [ Time Frame: 1 year ]
  • Keratometry measurements [ Time Frame: 1 year ]

Central Contacts and Locations

Central contacts

Sloan W Rush, MD

806-353-0125

Locations

Rush Eye Associates

Recruiting

Amarillo, Texas, United States, 79106

Contacts

Sunday Fowler

806-353-0125

Principal Investigator:

Sloan W Rush, MD

More Information

Sponsor

Rush Eye Associates

Last update posted

Oct 26, 2022

Last verified

Oct, 2022

Keywords

  • keratoconus, corneal collagen crosslinking, riboflavin, corneal ectasia

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Rush Eye Associates on 2022-10-26.